Technology Considerations to Enable the Risk-Based Monitoring Methodology

Abstract

TransCelerate BioPharma Inc developed a methodology based on the notion that shifting monitoring processes from an excessive concentration on source data verification to comprehensive risk-driven monitoring will increase efficiencies and enhance patient safety and data integrity while maintaining adherence to good clinical practice regulations. This philosophical shift in monitoring processes employs the addition of centralized and off-site mechanisms to monitor important trial parameters holistically, and it uses adaptive on-site monitoring to further support site processes, subject safety, and data quality. The main tenet is to use available data to monitor, assess, and mitigate the overall risk associated with clinical trials. Having the right technology is critical to collect and aggregate data, provide analytical capabilities, and track issues to demonstrate that a thorough quality management framework is in place. This paper lays out the high-level considerations when designing and building an integrated technology solution that will aid in scaling the methodology across an organization’s portfolio.